Durham, NC5 Active Studies

Lung Cancer Clinical Trials in Durham, NC

Find 5 actively recruiting lung cancer clinical trials in Durham, NC. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
1,612
Enrolling

Recruiting Lung Cancer Studies in Durham

RecruitingDurham, NCNCT05920356

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive...

750 participants
Amgen
View Study Details
RecruitingDurham, NCNCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...

530 participants
Bristol-Myers Squibb
View Study Details
RecruitingDurham, NCNCT05853575

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation....

200 participants
Mirati Therapeutics Inc.
View Study Details
RecruitingDurham, NCNCT07098988

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemot...

107 participants
CatalYm GmbH
View Study Details
RecruitingDurham, NCNCT06275360

Repositioning Immunotherapy in VetArans With Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC....

25 participants
VA Office of Research and Development
View Study Details

About Lung Cancer Clinical Trials in Durham

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 5 lung cancer clinical trials recruiting participants in Durham, NC. These studies are seeking a combined 1,612 participants. Research is being sponsored by Amgen, Bristol-Myers Squibb, Mirati Therapeutics Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Durham — FAQ

Are there lung cancer clinical trials in Durham?

Yes, there are 5 lung cancer clinical trials currently recruiting in Durham, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Durham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you about next steps.

Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Durham studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 5 active trials in Durham are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov